Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Equity Ratio (2020 - 2025)

Bioventus' Equity Ratio history spans 6 years, with the latest figure at 0.27 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 32.53% year-over-year to 0.27; the TTM value through Dec 2025 reached 0.27, up 32.53%, while the annual FY2025 figure was 0.27, 32.53% up from the prior year.
  • Equity Ratio reached 0.27 in Q4 2025 per BVS's latest filing, up from 0.24 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.5 in Q2 2022 to a low of 0.2 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.31, with a median of 0.28 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 70.02% in 2021, then plummeted 45.39% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.5 in 2021, then crashed by 39.42% to 0.3 in 2022, then fell by 9.2% to 0.27 in 2023, then fell by 25.47% to 0.2 in 2024, then skyrocketed by 32.53% to 0.27 in 2025.
  • Per Business Quant, the three most recent readings for BVS's Equity Ratio are 0.27 (Q4 2025), 0.24 (Q3 2025), and 0.28 (Q2 2025).